Log in to search using one of your social media accounts:

 

Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin
Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat/monkey/human liver microsomes and rat/monkey/dog/human hepatocytes. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 1, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Novel Macrocyclic Amidinoureas: Potent Non-Azole Antifungals Active against Wild-Type and Resistant Candida Species
Novelmacrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifungal agentsagainstwild-type and fluconazoleresistantCandidaspecies. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the invitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp.MK-3118 demonstrated enhanced efficacy for most C. albicans and C. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activity of statins against Aspergillus species
The cholesterol-lowering agents known as statins have in vitro activities against human pathogenic fungi, such as Candida species, Cryptococcus neoformans, and Zygomycetes. Synergy between statins and azoles against these fungi has also been reported. We evaluated the in vitro activities of two statins, lovastatin andsimvastatin, alone and in combination with azoles and amphotericin B, against clinical isolates ofAspergillus spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Statins are a class of drugs widely used for lowering high cholesterol levels through their action on 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in the synthesis of cholesterol. We studied the effects of two major statins,simvastatin and atorvastatin, on five Candida species andAspergillus fumigatus. The statins strongly inhibited the growth of all species, except Candida krusei. Supplementation of Candida albicans and A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin H
Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum antifungal activity, with sub- μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice
The activities ofR-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo.R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 microg/ml, respectively. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistantCandida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity againstCandida spp. bothin vitro andin vivo. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Drugs in Clinical Development for Fungal Infections (includes MAT023, encochleated amphotericin B))
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition
The synthesis and antifungal activity ofASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition and significantly improved MIC against Candida parapsilosis and echinocandin resistant-Candida is described. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

FR290581, a novel sordarin derivative: synthesis and antifungal activity
Sordarin is a unique natural product antifungal agent that is an inhibitor of elongation factor 2. To improve biological activity, we synthesized various compounds by novel modification of the aglycone, sordaricin. As a result, we have discovered the novel sordarin derivativeFR290581. This compound exhibited superior activity and a good pharmacokinetic profile, and also displayed good in vivo activity against Candida albicans. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding
The antifungal effect ofGM 237354, a sordarin derivative, was studied in an in vitro pharmacokinetic (PK)-pharmacodynamic dynamic system (bioreactor) which reproduces PK profiles observed in a previously described model of drug efficacy against murine systemic candidiasis. Immunocompetent mice infected intravenously with 10(5) CFU of Candida albicans were treated withGM 237354 at 2.5, 10, and 40 mg/kg of body weight every 8 h subcutaneously for 7 days. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

CDC Updates Guidance as Candida auris Cases Grow CDC Updates Guidance as Candida auris Cases Grow
Cases of the deadly yeast have increased exponentially in the past year in the US, leading the Centers for Disease Control and Prevention to recommend that labs identify species when Candida is found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

' Fungal Superbug' Raising Fears
(MedPage Today) -- But few Candida auris cases so far in U.S. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 5, 2017 Category: Primary Care Source Type: news

Drugs in Clinical Development for Fungal Infections (review includes CD101)
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Novamycin (NP339)
Novamycin ® (NP339) is a novel antifungal peptide developed forfront-line treatment of medically unmet, yeast and mould infections, particularly those caused by Aspergillus spp. and Candida spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Candida Crewe reveals how she overcame nausea
After hearing of the Duchess of Cambridge's plight, journalist Candida Crewe details her own experience with debilitating nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - September 25, 2017 Category: Consumer Health News Source Type: news

One writer reveals how she overcame nausea
After hearing of the Duchess of Cambridge's plight, journalist Candida Crewe details her own experience with debilitating nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - September 25, 2017 Category: Consumer Health News Source Type: news

How BIOHM's At Home Candida Test Is Giving Consumers Peace of Mind
How the scientist that named the mycobiome is using a simple at home test to give consumers an easy way to analyze the Candida in their guts. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 16, 2017 Category: Pharmaceuticals Authors: Afif Ghannoum, Contributor Source Type: news

Tackling an Invasive, Emerging, Multi-Drug Resistant Yeast: Candida Auris - What Healthcare Providers Need to Know
Centers for Disease Control and Prevention. 08/15/2017 This one-hour webinar describes the epidemiology of Candida auris (C. auris), an emerging multi-drug-resistant fungus that can cause invasive infections with high mortality, and has been associated with outbreaks in healthcare settings. It explains the guidance for diagnosis and treatment of C. auris, and the infection control recommendations for containing C. auris. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - September 12, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

T2 Biosystems files 510(k) for T2Bacteria Panel
T2 Biosystems Inc. (NSDQ:TTOO) said today it filed a 510(k) appliation with the FDA for its T2Bateria Panel rapid diagnostic solution designed to identify pathogens assocaited with Sepsis. The T2Bacteria panel is designed to run on the FDA-cleared T2Dx instrument to provide diagnosis of sepsis pathogens within hours, reducing the time for patients with bloodstream infections to receive treatment, the Lexington, Mass.-based company said. The submission includes data from a pivotal clinical trial of the T2Bacteria Panel which compared it to blood culture, as well as the performance of the panel in known bacteria positiv...
Source: Mass Device - September 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance T2 Biosystems Inc. Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 7, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Heraeus Medical Components acquires Biotectix Heraeus Medical Components is acquiring conductive polymer materials maker Biotectix. The deal, announced yesterday, will allow Heraeus to boost its medical electrode coating capabil...
Source: Mass Device - September 7, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

CDC to use T2 Biosystems in testing for superbug Candida auris
T2 Biosystems Inc. (NSDQ:TTOO) said today that the US Centers for Disease Control and Prevention will use its T2Dx Instrument to test and monitor for the emergence and outbreaks of the antibiotic-resistant superbug Candida auris. The Lexington, Mass.-based company said the use of the T2Dx “represents multiple, new applications” for the platform. The system will be used for the 1st time to test patient skin and blood samples and also for environmental surveillance and to monitor outbreaks. Both applications are currently available as research tools for investigational purposes in the US and Europe, T2 Biosy...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Diagnostics T2 Biosystems Inc. Source Type: news

Candida cleanse diet: What does it treat?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - September 6, 2017 Category: Consumer Health News Source Type: news

Candida Auris: A New Fungal Superbug Emerging As A Global Threat
For the first time, a new yeast, Candida auris, is found to be spreading from person to person in hospitals. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 24, 2017 Category: Pharmaceuticals Authors: Judy Stone, Contributor Tags: NYSE:PFE NYSE:MRK Source Type: news

The Unexpected and Troubling Rise of Candida auris The Unexpected and Troubling Rise of Candida auris
Behaving like a multidrug-resistant microbe, C auris is spreading rapidly throughout the world, including in healthcare facilities in the United States.CDC Expert Commentary (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2017 Category: Consumer Health News Tags: Infectious Diseases Commentary Source Type: news

IBS warning: Bloating and stomach pain could actually be too much of THIS
IBS - or irritable bowel syndrome - is a common digestive condition causing stomach pain and bloating. However, symptoms could actually be triggered by an overgrowth of a yeast called candida. (Source: Daily Express - Health)
Source: Daily Express - Health - August 22, 2017 Category: Consumer Health News Source Type: news

Trust distances itself from staffing link to fungus outbreak
A major London hospital trust has sought to distance itself from suggestions that a lack of nursing staff was implicit in an outbreak of the so-called “Japanese fungus” infection Candida auris. (Source: Nursing Times)
Source: Nursing Times - August 17, 2017 Category: Nursing Source Type: news

Lack of nurses blamed for the spread of Japanese fungus
King's College Hospital in South London was responsible for 31 cases of Candida auris fungus infections during a year-long outbreak, figures show. Bosses at its trust blamed a lack of nurses. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2017 Category: Consumer Health News Source Type: news

Tackling an Invasive, Emerging, Multi-drug Resistant Yeast: Candida auris - What Healthcare Providers Need to Know
August 15, 2017 2:00-3:00pm ET. (Source: HSR Information Central)
Source: HSR Information Central - August 11, 2017 Category: International Medicine & Public Health Source Type: news

Saliva 'may speed healing' but 'kissing it better' probably won't
Conclusion This complex study helps us understand the biological mechanisms behind wound healing in the mouth and the role of saliva in promoting wound healing. As well as keeping the mouth moist and reducing levels of harmful bacteria, saliva contains a protein that encourages the movement of cells in ways that help wounds to heal. It's possible this might lead to the development of new wound-healing treatments in future; however, this study didn't look at future uses – it simply helps us better understand how the body heals itself. Before any new treatment could be developed, further studies in cell lines and in an...
Source: NHS News Feed - August 10, 2017 Category: Consumer Health News Tags: Pregnancy/child Source Type: news

Effect of Split-File Digital Workflow on Crown Margin Adaptation
Explore this journal>Early ViewPrevious article in Early View: Impact of Denture Cleansing Solution Immersion on Some Properties of Different Denture Base Materials: An In Vitro StudyNext article in Early View: Nicotine Upregulates Coaggregation of Candida albicans and Streptococcus mutans Browse  Early View ArticlesOnline Version of Record published before inclusion in an issueFirst published:9 June 2017Full publication historyDOI:10.1111/jopr.12606 View/save citationCited by (CrossRef):0 articles Check for updatesAbstractPurposeComputer-aided design/computer-aided manufacturing (CAD/...
Source: Dental Technology Blog - June 28, 2017 Category: Dentistry Source Type: news

Scary, infectious SUPERBUG just spread to five more U.S. states, including some in the Midwest
(Natural News) A deadly, hard-to-spot “superbug” yeast is rapidly infiltrating American hospitals. In June 2016, the U.S. Centers for Disease Control and Prevention (CDC) warned clinics about the emergence of a new multidrug-resistant yeast strain called Candida auris. Two months later the first seven cases of a C. auris infection were recorded in the United... (Source: NaturalNews.com)
Source: NaturalNews.com - June 21, 2017 Category: Consumer Health News Source Type: news

Single fungus amplifies Crohn's disease symptoms
(Case Western Reserve University) A microscopic fungus called Candida tropicalis triggered gut inflammation and exacerbated symptoms of Crohn's disease, in a recent study conducted at Case Western Reserve University School of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2017 Category: International Medicine & Public Health Source Type: news

In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
Ann Clin Microbiol Antimicrob. 2013 Dec 5;12:37. doi: 10.1186/1476-0711-12-37.In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.Qiao J, Gao P, Jiang X, Fang H.BACKGROUND:Protein farnesylation is an important tosttranslational modification in fungi. We evaluated the antifungal activity of two farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
BACKGROUND:Protein farnesylation is an important posttranslational modification in fungi. We evaluated the antifungal activity of two farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.METHODS:Disk diffusion assay and broth microdilution assay were used to determine the antifungal susceptibility of two farnesyltransferase inhibitors (manumycin A and tipifarnib) against clinical isolates of Aspergillus and Candida. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Candida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species
Candida auris is a newly emerging species that was first identified in Asia in 2009 but has rapidly spread across the world. C. auris differs from most other Candida species in that antifungal resistance is the norm rather than the exception, it is a commensal of human skin rather than the human gut, and it can be easily transmitted from person to person in a health care setting. This review discusses the emergence of C. auris, global epidemiology, identification, antifungal susceptibility testing, and precautions to be taken when it is identified from a patient specimen. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - June 20, 2017 Category: Microbiology Authors: Shawn R. Lockhart, Elizabeth L. Berkow, Nancy Chow, Rory M. Welsh Source Type: news

Transmission of Candida auris in US Health Care Facilities Transmission of Candida auris in US Health Care Facilities
This report details the epidemiology of the first seven U.S. cases of infection with the emerging, and often multidrug-resistant, fungus Candida auris.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

An Open Letter To Gwyneth Paltrow About GOOP
Dear Ms. Paltrow, I understand you recently said that anyone who is going to f*ck with you better bring their A game.   I’m pretty sure you don’t mean comment on your recipes but rather the growing exasperation from medical professionals and journalists alike at the almost constant debunking of the health “advice” and all around medical bullshit that you and your pals at GOOP promote and sell. No, we don’t have adrenal fatigue we have goopitis. When I tell you that alcohol is a toxin I am not f*cking with you I am being factual. Do you really think everything in the world is a toxin exce...
Source: Healthy Living - The Huffington Post - June 1, 2017 Category: Consumer Health News Source Type: news

The scariest superbug on the CDC's radar has hit 7 states
The spread of Candida auris started in New York and New Jersey - but in the last month, new infections have been spotted in  Illinois, Indiana, Maryland, Massachusetts and Oklahoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 19, 2017 Category: Consumer Health News Source Type: news

Candida Auris, Often Drug-Resistant, Found in 7 States (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS As of mid-May 2017, a total of 77 clinical cases of Candida auris in U.S. health care facilities were reported to the CDC, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 19, 2017 Category: Primary Care Source Type: news

Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities — United States, June 2016–May 2017
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 18, 2017 Category: American Health Source Type: news

Candida auris: Emerging, Frequently Resistant, and Often Deadly Candida auris: Emerging, Frequently Resistant, and Often Deadly
Given frequent multidrug resistance, what drug therapy is appropriate for treating Candida auris?Medscape Pharmacists (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2017 Category: Consumer Health News Tags: Pharmacist Ask the Expert Source Type: news

Superbug FUNGUS now invading U.S. hospitals in NY and NJ ... All pharma drugs useless (but they refuse to use oregano oil)
(Natural News) The deadly superbug fungus known as Candida auris has continued to spread rapidly through hospitals in the U.S., mainly in the states of New York and New Jersey. When we last reported on the outbreak in March, there were 35 confirmed cases of the disease, 28 of them located in New York State.... (Source: NaturalNews.com)
Source: NaturalNews.com - May 10, 2017 Category: Consumer Health News Source Type: news

'Superbug' Fungus Outbreak in NY, NJ Hospitals
NEW YORK (AP) — A 'superbug' fungus is emerging as a new menace in U.S. hospitals, mostly in New York and New Jersey. First identified in Japan in 2009, the fungus has spread to more than a dozen countries around the globe. The oldest of the 66 cases reported in the U.S. dates back to 2013, but most were reported in the last year. The fungus called Candida auris is a harmful form of yeast. Scientists say it can be hard to identify with standard lab tests. U.S. health officials sounded alarms last year because two of the three kinds of commonly used antifungal drugs have little effect. "It's acting like a superbu...
Source: JEMS Patient Care - April 28, 2017 Category: Emergency Medicine Authors: Mike Stobbe,  AP Medical Writer Tags: News Patient Care Source Type: news

'Superbug' Fungus Outbreak in NY, NJ Hospitals
NEW YORK (AP) — A 'superbug' fungus is emerging as a new menace in U.S. hospitals, mostly in New York and New Jersey. First identified in Japan in 2009, the fungus has spread to more than a dozen countries around the globe. The oldest of the 66 cases reported in the U.S. dates back to 2013, but most were reported in the last year. The fungus called Candida auris is a harmful form of yeast. Scientists say it can be hard to identify with standard lab tests. U.S. health officials sounded alarms last year because two of the three kinds of commonly used antifungal drugs have little effect. "It's acting like a superbu...
Source: JEMS: Journal of Emergency Medical Services News - April 28, 2017 Category: Emergency Medicine Authors: Mike Stobbe,  AP Medical Writer Tags: News Patient Care Source Type: news

The scariest superbug on CDC's radar is a deadly fungus
Public health officials have revealed that a superbug - Candida auris, a harmful yeast - is on the CDC's radar after spreading to US hospitals, particularly in New York and New Jersey. (Source: the Mail online | Health)
Source: the Mail online | Health - April 26, 2017 Category: Consumer Health News Source Type: news

Your NEJM Group Today: Candida Esophagitis Images / New Approach to Hot Flashes? / FDA Medical Officer Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Image in Clinical Medicine: A 72-year-old man who … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 26, 2017 Category: Primary Care Source Type: news

Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Vulvovaginal candidiasis/candidosis is a common fungal infection afflicting approximately 75% of women globally caused primarily by the yeast Candida albicans. Fluconazole is widely regarded as the antifungal drug of choice since its introduction in 1990 due to its high oral bioavailability, convenient dosing regimen and favourable safety profile. However, its widespread use has led to the emergence of fluconazole-resistant C. albicans, posing a universal clinical concern. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 24, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Candin (Candida Albicans) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 11, 2017 Category: Drugs & Pharmacology Source Type: news